Pediatric refractory immune thrombocytopenia: A systematic review. Issue 3 (29th December 2022)

• Record Type: Journal Article
• Authors: Ibrahim, Layan; Dong, Selina X.; O'Hearn, Katie; Grimes, Amanda B.; Kaicker, Shipra; FritchLilla, Stephanie; Breakey, Vicky R.; Grace, Rachael F.; Lebensburger, Jeffrey D.; Klaassen, Robert J.; Lambert, Michele
• Is Part Of: Pediatric blood & cancer. Volume 70:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-29
• Subjects: child -- idiopathic -- purpura -- systematic review -- thrombocytopenic -- treatment failure -- treatment outcome; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.30173
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Pediatric immune thrombocytopenia (ITP) is an acquired disorder associated with autoimmune destruction and impairment of platelet production in children. Some children exhibit poor or transient response to ITP‐directed treatments and are referred to as having refractory ITP (rITP). There is currently no consensus on the definition of rITP, nor evidence‐based treatment guidelines for patients with rITP. After a survey of pediatric ITP experts demonstrated lack of consensus on pediatric rITP, we pursued a systematic review to examine the reported clinical phenotypes and treatment outcomes in pediatric rITP. The search identified 253 relevant manuscripts; following review, 11 studies proposed a definition for pediatric rITP with no consensus amongst them. Most definitions included suboptimal response to medical management, while some outlined specific platelet thresholds to define this suboptimal response. Common attributes identified in this study should be used to propose a comprehensive definition, which will facilitate outcome comparisons of future rITP studies.